Sandy Srinivas, MBBS, Stanford Cancer Center

Articles

Nonmetastatic CRPC: Treatment Selection

September 20th 2021

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

Advances in Nonmetastatic CRPC

September 20th 2021

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Oral GnRH Antagonist Therapy for mCSPC

September 13th 2021

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

mCSPC: Applying New Data into Clinical Practice

September 13th 2021

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

Triple Therapy Approaches for mCSPC

September 7th 2021

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

ADT Monotherapy in mCSPC

September 7th 2021

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

Incorporating Treatment Advances Into mRCC Management

August 24th 2021

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Emerging Therapies for Relapsed/Refractory mRCC

August 24th 2021

Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.

Relapsed/Refractory mRCC: Sequencing Therapy

August 17th 2021

Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.

Treatment Approaches for Relapsed/Refractory mRCC

August 17th 2021

An overview of treatment options for previously treated metastatic renal cell carcinoma.

Tissue and Liquid Biopsies in Advanced Prostate Cancer

August 16th 2021

Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.

Precision Medicine in Advanced Prostate Cancer

August 16th 2021

A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.

Adjuvant Therapy Approaches for Operable RCC

August 10th 2021

A summary of current therapies and ongoing investigations of adjuvant therapy for patients with operable renal cell carcinoma.

Therapies Under Investigation for Frontline mRCC

August 10th 2021

Novel therapies currently being investigated as frontline options for metastatic renal cell carcinoma.

Favorable-Risk mRCC: Treatment Approaches

August 3rd 2021

A panel discussion regarding individual preferences for treating favorable-risk metastatic renal cell carcinoma.

Favorable-Risk mRCC: When to Initiate Therapy

August 3rd 2021

Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.

Intermediate/Poor-Risk mRCC: Treatment Selection

July 27th 2021

Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.

Intermediate/Poor-Risk mRCC: I-O/I-O Vs I-O/TKI Therapy

July 27th 2021

Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.

I-O/TKI Regimens for Metastatic RCC: Dosing Strategies

July 20th 2021

Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.

The CLEAR Trial in Metastatic RCC

July 20th 2021

Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.